JP7889788B2 - ナノ材料のためのイオン化可能な脂質 - Google Patents
ナノ材料のためのイオン化可能な脂質Info
- Publication number
- JP7889788B2 JP7889788B2 JP2023538794A JP2023538794A JP7889788B2 JP 7889788 B2 JP7889788 B2 JP 7889788B2 JP 2023538794 A JP2023538794 A JP 2023538794A JP 2023538794 A JP2023538794 A JP 2023538794A JP 7889788 B2 JP7889788 B2 JP 7889788B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- saturated
- branched
- hydrocarbon chain
- lnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139730P | 2021-01-20 | 2021-01-20 | |
| US63/139,730 | 2021-01-20 | ||
| PCT/US2022/012867 WO2022159421A1 (en) | 2021-01-20 | 2022-01-19 | Ionizable lipids for nanomaterials |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502948A JP2024502948A (ja) | 2024-01-24 |
| JP2024502948A5 JP2024502948A5 (cg-RX-API-DMAC10.html) | 2025-01-24 |
| JP7889788B2 true JP7889788B2 (ja) | 2026-07-14 |
Family
ID=82549646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538794A Active JP7889788B2 (ja) | 2021-01-20 | 2022-01-19 | ナノ材料のためのイオン化可能な脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230348359A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4281114A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7889788B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN116782951A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022210299A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3203784A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022159421A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| CN115175894B (zh) | 2020-01-09 | 2024-09-06 | 盖德治疗有限责任公司 | 纳米材料 |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025035202A1 (en) * | 2023-08-04 | 2025-02-20 | Nanovation Therapeutics Inc. | Ionizable lipids comprising macrocyclic rings for the delivery of therapeutic agents |
| EP4762030A1 (en) * | 2023-08-16 | 2026-06-24 | Beam Therapeutics Inc. | Ionizable lipids with branched head groups |
| WO2025137243A1 (en) * | 2023-12-19 | 2025-06-26 | Amplitude Therapeutics, Inc. | Methods for measuring self-amplifying rna and trans amplifying rna activity in vivo |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014115473A (ja) | 2012-12-10 | 2014-06-26 | Konica Minolta Inc | 光学フィルムのロール体とその製造方法、包装体、偏光板および液晶表示装置 |
| JP2014534220A (ja) | 2011-10-27 | 2014-12-18 | マサチューセッツ インスティテュート オブ テクノロジー | 薬物内包微小球の形成が可能なn−末端で官能基化されたアミノ酸誘導体 |
| WO2015095340A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| JP2017500865A (ja) | 2013-12-19 | 2017-01-12 | ノバルティス アーゲー | レプチンmRNAの組成物および製剤 |
-
2022
- 2022-01-19 AU AU2022210299A patent/AU2022210299A1/en active Pending
- 2022-01-19 EP EP22743057.6A patent/EP4281114A4/en active Pending
- 2022-01-19 CA CA3203784A patent/CA3203784A1/en active Pending
- 2022-01-19 JP JP2023538794A patent/JP7889788B2/ja active Active
- 2022-01-19 WO PCT/US2022/012867 patent/WO2022159421A1/en not_active Ceased
- 2022-01-19 CN CN202280008627.4A patent/CN116782951A/zh active Pending
-
2023
- 2023-07-12 US US18/220,874 patent/US20230348359A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014534220A (ja) | 2011-10-27 | 2014-12-18 | マサチューセッツ インスティテュート オブ テクノロジー | 薬物内包微小球の形成が可能なn−末端で官能基化されたアミノ酸誘導体 |
| JP2014115473A (ja) | 2012-12-10 | 2014-06-26 | Konica Minolta Inc | 光学フィルムのロール体とその製造方法、包装体、偏光板および液晶表示装置 |
| WO2015095340A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| JP2017500865A (ja) | 2013-12-19 | 2017-01-12 | ノバルティス アーゲー | レプチンmRNAの組成物および製剤 |
Non-Patent Citations (1)
| Title |
|---|
| Melissa P. LOKUGAMAGE et al.,"Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands",Advanced Materials,2019年08月29日,Vol. 31, No. 41,DOI: 10.1002/adma.201902251 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3203784A1 (en) | 2022-07-28 |
| AU2022210299A1 (en) | 2023-06-29 |
| WO2022159421A1 (en) | 2022-07-28 |
| EP4281114A4 (en) | 2025-08-06 |
| EP4281114A1 (en) | 2023-11-29 |
| US20230348359A1 (en) | 2023-11-02 |
| JP2024502948A (ja) | 2024-01-24 |
| CN116782951A (zh) | 2023-09-19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250116 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260424 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260602 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260618 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7889788 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |